Related Experiment Video
Updated: Dec 1, 2025
09:28
Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells
Published on: February 2, 2013
15.5K
A multivariate, quantitative assay that disentangles key kinetic parameters of primary human T cell function in vitro
Grace L Huang1, Daniel P Nampe1, Jason Yi1
1Discovery Research, A2 Biotherapeutics, Inc., Agoura Hills, California, United States of America.
Plos One
|November 9, 2020
Summary
A new T cell assay quantifies engineered T cell function, separating proliferation from cytotoxicity. This advance aids preclinical development of cell therapies like CAR-T and TCR-T for cancer treatment.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Cell therapy, particularly immuno-oncology, is rapidly advancing.
- Engineered T cell therapies (CAR-T and TCR-T) show promise but face analytical challenges in preclinical development.
- Current assays struggle to comprehensively assess engineered T cell function, especially in the peptide-MHC (pMHC) context.
Purpose of the Study:
- To develop a novel, quantitative, high-content assay for analyzing engineered T cell function.
- To address limitations in existing multivariate assays for preclinical T cell therapy development.
- To disentangle key functional parameters like proliferation and cytotoxicity.
Main Methods:
- Development of an imaging-based primary T cell assay.
- Quantitative, high-content analysis of T cell responses.
- Separation of time- and antigen-dependent proliferation from cytotoxicity.
Main Results:
- The assay successfully distinguishes T cell proliferation from cytotoxicity.
- It provides insights into CAR-T and TCR-T cell biology.
- Demonstrates the ability to analyze response kinetics and effector:target ratios.
Conclusions:
- This novel assay offers a robust tool for the preclinical assessment of engineered T cells.
- It advances the analytical capabilities for cell therapy development.
- Facilitates a deeper understanding of CAR-T and TCR-T cell behavior.
